Insider Transactions in Q2 2025 at Replimune Group, Inc. (REPL)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,105
-6.81%
|
$200,840
$8.06 P/Share
|
|
May 20
2025
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,287
-4.59%
|
$26,296
$8.05 P/Share
|
|
May 20
2025
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,952
-5.13%
|
$63,616
$8.06 P/Share
|
|
May 20
2025
|
Philip Astley Sparke Director |
SELL
Open market or private sale
|
Direct |
32,279
-2.25%
|
$258,232
$8.06 P/Share
|
|
May 20
2025
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,749
-2.84%
|
$29,992
$8.05 P/Share
|
|
May 20
2025
|
Emily Luisa Hill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,535
-1.74%
|
$20,280
$8.05 P/Share
|
|
Apr 01
2025
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
166,667
+31.13%
|
-
|
|
Apr 01
2025
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Grant, award, or other acquisition
|
Direct |
33,333
-31.77%
|
-
|
|
Apr 01
2025
|
Christopher Sarchi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+25.42%
|
-
|
|
Apr 01
2025
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+23.55%
|
-
|
|
Apr 01
2025
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+22.51%
|
-
|